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Objective. To determine the relationship between FCGR3B gene copy number variation (CNV) and biopsy proven giant cell arteritis
(GCA). Methods. FCGR3B CNV was determined in 139 Australian biopsy proven GCA patients and 162 population matched
controls, using a duplex qPCR assay and RNase P as the reference gene. Copy number was determined using Copy Caller software
(v.1.0, Applied Biosystems, USA). CNV genotypes were classified into 3 groups (<2, 2, 3+) for analysis purposes, and analysis
was performed using logistic regression. Results. All GCA patients had a positive temporal artery biopsy, and the most common
presenting symptoms were visual disturbance and temporal headache. The mean age of patients at biopsy was 74 years (range
51–94) and 88/139 (63%) were female. The frequency of low (<2) FCGR3B copy number was comparable between GCA patients
(9/139 = 6.5%) and controls (10/162 = 6.2%), as was the frequency of high (3+) FCGR3B copy number (15/130 (10.8%) in GCA
patients versus 13/162 (8.0%) in controls). Overall there was no evidence that FCGR3B CNV frequencies differed between GCA
patients and controls (𝜒2 = 0.75, 𝑑𝑓 = 2, 𝑃 = 0.69). Conclusion. FCGR3B CNV is not associated with GCA; however, replicate
studies are required.
1. Introduction
Giant cell arteritis (GCA), also known as temporal arteritis, is
a systemic inflammatory vasculitis which primarily affects
medium to large extracranial arteries of the head and neck
and can result in stroke and blindness. GCA typically affects
people aged over 50 years and incidence rates increase with
advancing age, peaking around 80 years of age [1]. GCA is 2-
3 times more likely to affect females and is more commonly
diagnosed inCaucasians than in any other ethnic background
with the highest incidence observed in populations of Scan-
dinavian descent [2].
The pathogenesis of GCA is not understood, although
environmental, infectious, and genetic risk factors have been
implicated. Familial aggregation and established associations
with HLA-DR4 provide evidence for a genetic component to
GCA [3–5]. Multiple genetic association studies have been
performed on a number of immune response genes.However,
the majority of these studies have been performed on a single
GCA cohort from north-western Spain and, to date, have
failed to confirm any additional genetic associations.
One gene of interest is Fc gamma receptor 3B (FCGR3B)
which exhibits gene copynumber variation (CNV), an impor-
tant source of quantitative genetic variation. Copy number
variation is a departure from the normal diploid number of
genes (𝑛 = 2) which may arise through gene duplication and
deletion events. An increasing number of CNVs have been
characterised in the human genome with implications for
both evolution and disease susceptibility [6]. CNV has been
well characterised in the FCGR gene cluster on chromosome
1q23. This cluster carries five highly homologous genes that
encode for low-affinity receptors for IgG-complexed antigens,
which are expressed widely throughout the haematopoietic
system. These low-affinity Fc-gamma receptors are involved
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in the regulation of a multitude of innate and adaptive
immune responses, with implications for both response to
infection and susceptibility to autoimmunity [7].
CNV in the FCGR3B gene is of particular interest.
FCGR3B is expressed almost exclusively on neutrophils [7],
and there is a clear correlation between gene copy number
and FCGR3B cell surface expression, neutrophil adherence to
IgG-coated surfaces, and immune complex uptake [8]. Fur-
ther, multiple studies have identified low FCGR3B CN (i.e.,
<2 copies) as a risk factor for systemic autoimmune diseases,
such as systemic lupus erythematosus [9–11], rheumatoid
arthritis [12, 13], primary Sjo¨gren’s syndrome [10, 11], and scle-
roderma [14], which is interpreted in terms of the important
role that Fc receptors play in the clearance of immune com-
plexes. In contrast, given the importance of neutrophil acti-
vation in vascular inflammation [15], it is plausible that high
FCGR3B copy number may in fact predispose to receptor-
mediated neutrophil activation and therefore vasculitis.
Previous studies in relation to FCGR3B CNV and vas-
culitis are inconclusive. Associations have been reported with
both low [9] and high [8] copy number, whilst other studies
have not identified such an association (reviewed in [16]).
We have also previously reported that FCGR3B CNV is not
a risk factor for Behcet’s disease [17] in Iranian patients. The
aim of this study was to evaluate the association between
FCGR3B CNV and biopsy-proven GCA in an Australian
patient cohort.
2. Materials and Methods
2.1. Subjects. One hundred and thirty-nine Australian
biopsy-proven GCA patients were recruited through the
South Australian Giant Cell Arteritis Registry and the Royal
Victorian Eye andEarHospital.This study has ethics approval
from the Queen Elizabeth Hospital, Royal Adelaide Hospital,
Repatriation General Hospital and Flinders Medical Centre
in South Australia, and the Royal Victorian Eye and Ear
Hospital in Victoria, and all participants provided written,
informed consent. A total of 162 population controls (53%
female, median age 56 years) were used for comparison.
2.2. FCGR3B Copy Number Typing. Genomic FCGR3B copy
number was assessed using a custom TaqMan quantitative
real-time PCR (qPCR) method, as previously described [11,
12, 17]. Briefly, a duplex TaqMan copy number assay was
performed, using FCGR3B-specific primers (Applied Biosys-
tems, Hs04211858, FAM-MGB dual-labeled probe) and
RNase P (Applied Biosystems, product 4403326, VIC-
TAMRA dual-labeled probe) as the reference assay.The assay
was performed according to the manufacturer’s instructions,
and PCR reactions were run on an Applied Biosystems
7300 Real-Time PCR machine. All samples were tested in
triplicate, and fluorescence signals were normalised to ROX.
Copy number was determined using Copy Caller software
(v.1.0, Applied Biosystems, USA), and results were accepted
only when calling confidence was >80% and ΔCq standard
deviation between replicates was <0.20.
Table 1: Demographic features and presenting symptoms of patients
with giant cell arteritis. Clinical data at presentation was not
available for all patients.
Age at diagnosis, median (range) 74 years (51–94)
Gender, % female 88/139 (63%)
Temporal artery biopsy positive 139/139 (100%)
Visual disturbance 57/78 (73%)
Temporal headache 70/77 (65%)
Jaw claudication 46/78 (58%)
Scalp tenderness 37/78 (47%)
Loss of vision 21/71 (30%)
2.3. Statistical Analysis. Analysis of FCGR3B CNV was per-
formed using logistic regression. Effect sizes were reported as
odds ratios (OR) with 95% confidence intervals (95% CI).
3. Results
The demographic characteristics of the GCA patients are dis-
played in Table 1. All patients had a positive temporal artery
biopsy.Themean age of patients at biopsy was 74 years (range
51–94) and 88/139 (63%) were female.
Five different copy number variant genotypes were
observed in this study, corresponding to 0, 1, 2, 3, 4 FCGR3B
copies in a diploid individual. Because 0 and 4 copies were
infrequent, genotypes were classified into 3 groups (< 2, 2, 3+)
for analysis purposes.Themost common FCGR3B gene copy
number was 2 (normal diploid number) which was identified
in 139/162 (86%) of controls and 114/138 (83%) of GCA
patients (Table 2). There was no evidence that the overall
distribution of FCGR3BCNVgenotypes differed significantly
betweenGCApatients and controls (global𝜒2 = 0.75,𝑑𝑓 = 2,
𝑃 = 0.69) nor was there any evidence of a specific difference
between GCA patient and controls for low (<2, 𝑃 = 0.85) or
high (3+, 𝑃 = 0.39) FCGR3B copy number (Table 2).
4. Discussion
Whilst an association between FCGR3B low copy number
(<2) and susceptibility to systemic autoimmune diseases is
well established, with potential mechanisms relating to
receptor clearance of immune complexes, and perhaps the
most plausible hypothesis in relation to vasculitis is that
high FCGR3B copy number may predispose via increased
receptor-mediated neutrophil activation. This is the first
study to examine the relationship between FCGR3B CNV
and susceptibility to biopsy-proven GCA, and we report no
evidence of an association with either high or low copy
number.
Previous studies have reported intriguing, but conflicting,
relationships betweenFCGR3B copy number and vasculitis in
the context of different diseases. Both low and high FCGR3B
copy number (<2) have been associated with anti-neutrophil
cytoplasmic antibody-associated systemic vasculitides [8, 9],
with a third study [18] observing no association.Other studies
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Table 2: FCGR3B gene copy number distribution in GCA patients and controls. Odds ratios (OR) and 𝑃 values were derived by logistic
regression, with the normal diploid copy number (2) selected as the reference category.
FCGR3B copy number Control𝑁 = 162 (%) GCA𝑁 = 138 (%) OR (95% CI) 𝑃 Value
<2 10 (6.2) 9 (6.5) 1.1 (0.4, 2.8) 0.85
2 139 (85.8) 114 (82.6) 1 —
3+ 13 (8.0) 15 (10.8) 1.4 (0.6, 3.1) 0.39
Chi-squared = 0.75, degrees freedom = 2, and 𝑃 value = 0.69.
have reported no FCGR3B CNV associations with Kawasaki
disease [19], antiglomerular basement membrane disease
[20], and Behcet’s disease [17] nor with vasculitis complicat-
ing systemic lupus erythematosus [21].
The FCGR gene cluster is a complex genomic region, with
both SNP and CNV polymorphism.While we were unable to
demonstrate an association between FCGR3B copy number
and GCA in this study, there are putative links to poly-
morphism in this region with systemic vasculitides, as SNPs
within theFCGR gene cluster have been associatedwithGCA,
Behcet’s diseases and Kawasaki’s disease [22, 23]. However,
the high degree of sequence homology between the segmental
duplications in the FCGR cluster has hindered sequence
annotation and unambiguous SNP mapping in this region,
and therefore the interpretation and replication of these
studies are unclear.
The strength of our study is the selection of patients with
biopsy confirmation of GCA, allowing accurate ascertain-
ment of cases. A limitation of our study is its relatively small
sample size. The relatively wide effect size confidence inter-
vals indicate that an association between GCA and either
low or high FCGR3B copy number cannot be definitively
excluded on the results of this study alone, and future repli-
cation studies are required. In general, genetic association
studies with GCA have been hindered by the difficulties in
collection of DNA samples from elderly patients in an essen-
tially rare, late onset disease. Previously published genetic
studies for GCA all have similarly small patient samples sizes,
and indeed there is a paucity of different GCA patient cohorts
for this type of research. International collaboration will be
essential to collect large patient datasets and samples, with
prospective recruitment at the time of diagnosis optimal for
capturing appropriate samples with accompanying clinical
and laboratory data.
5. Conclusion
The results of this study indicate that FCGR3B copy number
variation is not a risk factor for GCA. Larger replication stud-
ies will be required to definitively establish any relationship
between FCGR3B CNV and GCA and indeed other vasculi-
tides.
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